A ureteral stent is configured for improved patient comfort and aftercare. The stent can have one or more of the following features: a distal portion with a somewhat flattened, non-circular cross-section that provides reduced irritation and elimination of urine reflux; a proximal portion with a helical coil shape that allows self-anchoring of the stent below the kidney; and a portion along the body of the stent having a coil shape that allows self-adjustment of the stent with ureteral movement.
|
11. A ureteral stent comprising an elongated, substantially hollow body having a proximal portion and a distal portion, wherein at least part of said proximal portion forms a substantially helical coil shape that is configured to self-anchor inside an upper portion of a ureter below a kidney, in an unconstrained state at least a portion of said distal portion defines a lumen having a substantially non-circular cross-section.
30. A ureteral stent comprising an elongated, substantially hollow body having a proximal portion configured for placement in at least one of a ureter and a kidney of a patient and a distal portion defining a lumen and configured for placement in a bladder of the patient, wherein in an unconstrained state at least a first part of said distal portion has an outer perimeter having a non-circular cross-section and at least a second part of said distal portion forms a substantially spiral shape to retain an end of the stent within the bladder.
1. A ureteral stent for reducing tissue irritation comprising an elongated, substantially hollow body having a proximal portion configured for placement in at least one of a ureter and a kidney of a patient and a distal portion configured for placement in a bladder of the patient, wherein in an unconstrained state at least a first part of said distal portion defines a lumen having an elliptical cross-section and at least a second part of said distal portion forms a substantially spiral shape to retain an end of said stent within the bladder.
23. A ureteral stent comprising an elongated, substantially hollow body having a proximal portion and a distal portion, wherein at least part of said proximal portion forms a substantially helical coil shape that is configured to self-anchor inside an upper portion of a ureter below a kidney, and wherein in an unconstrained state at least part of said distal portion defines a lumen having a substantially non-circular cross-section, and wherein at least part of said body forms a substantially helical coil shape to enable said body to self-adjust with patient movement.
38. A ureteral stent for reducing tissue irritation comprising an elongated, substantially hollow body having a proximal portion configured for placement in at least one of a ureter and a kidney of a patient and a distal portion configured for placement in a bladder of the patient, in an unconstrained state at least a first part of said distal portion defines a lumen having a substantially non-circular cross-section, at least a section of said distal portion of said hollow body has a wall thickness that is thinner than the wall thickness of at least a section of said proximal portion.
37. A ureteral stent comprising an elongated, substantially hollow body having a proximal portion configured for placement in at least one of a ureter and a kidney of a patient and a distal portion, said distal portion including a first part and a second part, said first part of said distal portion defining a lumen and being configured to contact a ureteral vesical junction, said second part of said distal portion configured for placement in a bladder of the patient, in an unconstrained state an outer perimeter of said first part of said distal portion has a non-circular cross-section.
19. A ureteral stent comprising an elongated, substantially hollow body having a proximal portion and a distal portion, said body defining a lumen extending from said proximal portion to said distal portion and configured to convey urine from a ureter of a patient to a bladder of the patient, at least part of said proximal portion forms a first substantially helical coil shape configured to self-anchor inside an upper portion of the ureter below a kidney of the patient, and wherein at least part of said body forms a second substantially helical coil shape to enable said body to self-adjust with patient movement.
14. A ureteral stent comprising an elongated, substantially hollow body having a proximal portion and a distal portion, said body defining a lumen extending from said proximal portion to said distal portion and configured to convey urine from at least one of a kidney and a ureter of a patient to a bladder of the patient, said proximal portion including a retention member configured to help retain at least a portion of the ureteral stent within the at least one of a kidney and a ureter of the patient, wherein at least a part of said body forms an irregular helical coil shape to enable said body to self-adjust with patient movement.
24. A method of self-adjusting a ureteral stent to compensate for patient movement, the method comprising the steps of:
(a) providing a ureteral stent comprising an elongated, substantially hollow body having a proximal portion and a distal portion, wherein at least part of said body forms a substantially helical coil shape and at least part of said distal portion of said body defines a lumen having a substantially non-circular cross-section;
(b) anchoring said proximal portion inside an upper portion of a ureter below a kidney; and
(c) self-adjusting said ureteral stent by allowing patient movement to impart motion on at least a portion of said body in response to a movement of said ureter.
2. The stent of
3. The stent of
4. The stent of
5. The stent of
6. The stent of
10. The stent of
12. The stent of
13. The stent of
15. The ureteral stent of
16. The ureteral stent of
17. The ureteral stent of
20. The ureteral stent of
21. The ureteral stent of
22. The ureteral stent of
25. The method of
26. The method of
27. The method of
28. The method of
29. The method of
31. The stent of
32. The stent of
33. The stent of
34. The stent of
35. The stent of
36. The stent of
|
The invention relates generally to stents; more particularly, the invention relates to ureteral stents.
A ureter is a tubular passageway in the body that conveys urine from a kidney to a bladder. Blockages of the ureter may cause hydronephrosis, a condition characterized by damming of urine in the kidneys, resulting in swelling and inflammation of the upper urinary tract and the kidneys. This may lead to kidney dysfunction and eventual necrosis. Ureteral blockages, also called ureteral strictures, may be congenital or acquired. Acquired blockages may be caused by disease, injury, kidney stones, and tumors. Both congenital and acquired blockages generally require medical intervention, for example, the use of ureteral stents.
Ureteral stents are used to facilitate urinary drainage from the kidney to the bladder in patients having a ureteral obstruction or injury, or to protect the integrity of the ureter in a variety of surgical manipulations. Ureteral stents are typically about 30-cm long, hollow catheter-like devices composed of a polymer and placed within the ureter with the proximal end residing in the kidney and the distal end in the bladder. Ureteral stents function by channeling the flow of urine from the kidney to the bladder. One or both ends of a ureteral stent may be coiled in a pigtail shape to prevent the upward and/or downward migration of the stent due to patient movement. The ureter may stretch up to 5 cm in either direction during a patient's normal bodily movements, such as movement during breathing. If the stent is not sufficiently anchored, this may result in stent migration and displacement. Also, a stent may cause tissue irritation due to the relative movement between the stent and the ureter during natural stretching of the ureter, even when the stent is properly anchored. A typical semi-rigid, anchored stent is unable to adjust for the natural extension and contraction of the ureter during bodily movements, resulting in pressure and irritation of the ureter and surrounding tissue.
Regions of tissue most vulnerable to stent-induced irritation include the kidney, the renal pelvis, the sensitive bladder tissue in the trigonal region, and the tissue of the ureteral vesical junction leading into the bladder. Irritation may be caused by the static or dynamic contact of the semi-rigid stent with sensitive tissues of the body, such as the kidney and the renal pelvis. Chronic trigonal tissue irritation may result from contact of tissue by the bladder-anchoring features of the stent, for example, pigtails at the stent ends. Irritation problems are of concern regardless of the duration of use of the stent; however, irritation is of particular concern where use of a stent is required over a long period of time.
Another problem associated with ureteral stents is urine reflux and pain during urine voiding. On the initiation of voiding, the bladder wall muscles contract causing the pressure inside the bladder to increase. Because a typical ureteral stent holds the ureteral orifice open, increased bladder pressure during voiding is transmitted to the kidney through the stent, causing urine reflux and flank pain.
The invention provides a ureteral stent configured to address a variety of sources of irritation associated with the use of conventional ureteral stents. These irritations include, for example, irritation in the trigonal region of the bladder due to semi-rigid stent contact with bladder mucosa, ureteral vesical junction irritation caused by extension of this region beyond a typical relaxation conformation, pain in the kidney and/or renal pelvis due to the presence therein of part of a semi-rigid stent, and flank pain associated with urine reflux during voiding of the bladder.
The invention features a stent that addresses these sources of irritation by including one or more of the following features: a portion at the distal end having a non-circular cross-section; a proximal portion having a helical coil shape configured to allow anchoring of the stent below the kidney and at or below the renal pelvis; and a portion having an irregular coil shape to allow self-adjustment of the stent with ureteral movement.
In one embodiment, the distal portion of the stent includes a section of hollow tube with a non-circular (e.g., somewhat flattened) profile. The non-circular profile is intended to more closely follow the contour of the intramural tunnel and ureteral vesical junction than does a circular profile. Extension or widening of the cross-section of the ureteral vesical junction due to the presence of the stent is minimized. Thus, there is less irritation caused by the stent at the ureteral vesical junction. The non-circular-profile section of the stent also provides a more flexible, less rigid distal end portion that eases pain and irritation, for example, in the trigonal region of the bladder.
The non-circular-profile section of the stent also provides for the reduction or elimination of urine reflux from the bladder to the kidney during voiding, thereby preventing the associated flank pain. Pressure external to the stent at the non-circular-profile section of the stent collapses the stent shut during voiding of the bladder and prevents reflux of urine to the kidney. After voiding, the stent opens again upon resumption of a normal bladder pressure. The non-circular-profile section of the stent may be made even more flexible and collapsible by the use of a thinner wall thickness in this section. In an embodiment, the distal portion of the stent is anchored in the bladder by a pigtail-shaped end portion, at least part of which has a non-circular cross-section to allow reduced irritation in the bladder and in the urinary vesical junction region.
In another embodiment, the ureteral stent has a proximal portion configured to self-anchor inside an upper portion of the ureter, at or below the renal pelvis, to minimize or eliminate stent irritation in the kidney and/or the sensitive renal pelvis region. In one embodiment, a substantially three-dimensional helical coil shape of sufficiently large helix diameter provides an anchor inside the upper portion of the ureter. By anchoring the stent below the kidney, irritation is minimized in the sensitive renal pelvis region.
Another embodiment provides a stent with a portion forming an irregular helical coil shape to enable the stent to self-adjust with patient movement, thereby reducing irritation due to normal stretching and conformational change of the ureter. The irregular helical coil shape provides a self-adjusting reserve of stent length to allow for stent elongation, contraction, and other conformation change caused by movement of the ureter. The irregular helical coil shape may also provide an additional source of support for the stent within the ureter. In one embodiment, a stent has an irregular helical coil shape along its length, as well as a proximal end portion having a regular helical shape for anchoring the stent below the kidney. The portion of the stent having an irregular helical coil shape may be configured with sufficient helix diameter and height of helix extension so that (1) the proximal portion of the stent is more stably anchored below the kidney, and (2) the stent self-adjusts by elongating and contracting with patient movement. In one embodiment, the irregular helical coil shape has an increasing height of helix extension—fewer turns per unit length—toward the distal portion of the stent near the bladder. The irregular nature of the helical coil shape in this embodiment better follows the anatomy of the ureter than would a regular helical coil shape, and provides reduced stent weight, reduced pressure against ureteral tissue, and reduced irritation to the local tissue without compromising the self-anchoring ability of the stent. In an alternative embodiment, the stent has a portion forming a substantially regular helical coil shape to enable the stent to self-adjust with patient movement.
The objects and features of the invention can be better understood with reference to the drawings described below, and the claims. The drawings are not necessarily to scale, emphasis instead generally being placed upon illustrating the principles of the invention. In the drawings, like numerals are used to indicate like parts throughout the various views.
The invention provides a ureteral stent configured for improved patient comfort and aftercare. In one embodiment, the stent has a distal portion with a somewhat flattened, non-circular cross-section, thereby providing a more flexible, less rigid, self-aligning lumen in the sensitive trigonal region of the bladder. In another embodiment, the stent features a proximal portion with a helical coil shape to allow self-anchoring of the stent below the kidney, at or below the renal pelvis. Furthermore, one embodiment includes a stent with a portion along its length having an irregular coil shape to allow self-adjustment of the stent with ureteral movement. Other embodiments of the invention include stents with various combinations of the aforementioned features.
Additionally, the invention provides a method of self-adjusting the effective length of a ureteral stent to compensate for patient movement, thereby providing improved patient comfort. An embodiment of the method includes providing a ureteral stent with a portion of its length having an irregular coil shape, anchoring the proximal portion of the stent inside the upper portion of the ureter below the kidney, and allowing the stent to self-adjust in response to patient movement. Patient movement, such as movement during breathing, causes the length of the stent to expand or contract in response to the natural movement of the ureter. Anchoring the stent below the kidney and at or below the renal pelvis provides increased comfort and reduced irritation to the kidney and/or the renal pelvis. The stent used in this method may have any combination of the stent features described herein.
Ureteral stents of the present invention are used, for example, to facilitate urinary drainage from the kidney to the bladder in patients having ureteral obstructions or injuries, or to protect the integrity of the ureter in a variety of surgical manipulations. A patient may undergo either short-term or long-term ureteral stenting. Short term stenting generally lasts up to a period of a weeks, and long-term stenting may last for a period of months or years. In addition to facilitating urinary draining through obstructed ureters, stenting may be used as an adjunct to open surgical procedures of the urinary tract to provide a mold around which healing can occur, or to divert the urinary flow away from areas of leakage. Other uses of stents of the present invention include, for example, maintaining the functionality of ureters following balloon dilation or incision of ureteral strictures, manipulating or preventing kidney stone migration prior to treatment, and making ureters more easily identifiable during difficult surgical procedures. Additionally, ureteral stents of the present invention may be used in those with active kidney infection or with markedly diseased, intolerant bladders, such as bladders damaged from radiation therapy, or bladders invaded by adjacent neoplasm.
The flattened section along the distal portion 102 of the stent 100 also provides for the elimination of urine reflux from the bladder 306 to the kidney 302 during voiding, thereby preventing the associated flank pain. During voiding, the pressure in the bladder 306 increases. Pressure external to both the stent 100 at the flattened section and to the bladder wall at the ureteral vesical junction 308 collapses the stent 100 shut at the flattened section during voiding of the bladder 306 and prevents reflux of urine up to the kidney 302. After voiding, the stent 100 opens again, upon resumption of a lower pressure in the bladder 306.
The flattened section of the distal portion 102 of the stent 100 also allows for self-alignment of the stent within the lower ureter 304. If, upon implantation, the stent 100 is not properly aligned such that the wide part of the profile of the flattened portion of the stent 100 aligns with the wide part of the profile of the ureter 304 along the ureteral vesical junction 308, natural movement of the ureter will cause the stent to self-align.
The irregular helical coil shape 104 of the stent 100 shown in
In one embodiment, the ureteral stent is made of at least one of group of biocompatible plastic materials, including but not limited to polyester-based biocompatible polymers, nylon-based biocompatible polymers, polytetrafluoroethylene (PTFE) polymers, silicone polymers, polyurethane polymers, silicone polyurethane polymers, polyethylene polymers, and thermoplastic polymers, for example. In an embodiment in which it is necessary that the stent undergo significant conformation changes—for example, during implantation—the stent may be constructed from shape memory tubing, such as PERCUFLEX® (Boston Scientific Corporation, Natick, Mass.), C-FLEX® (Xomed-Trease, Inc.), FLEXIMA™, or other polymer material, for example. The stent may have a hydrogel coating, which offers a further reduction of irritation due to contact of the stent with tissue. The stent may be made of a biodegradable polymer, for example, where it is desired that the stent dissolve in-situ after its useful lifetime in the patient.
In an embodiment featuring a stent with a somewhat flattened distal portion, the stent may be created, for example, using single extrusion where one end of the extruded material is round and the other end is flattened. The flattened portion may be achieved, for example, by applying pressure to the heated extrudate. The flat portion provides greater flexibility, more closely resembles the profile of the ureteral vesical junction, allows for self-alignment of the stent, and prevents urine reflux during voiding by collapsing shut upon application of sufficient natural external pressure. In addition to use of a flattened cross-section, the distal portion can be made more flexible by use of a softer material. For example, a softer and more flexible pigtail at the distal end of the stent may be made by bonding a distal portion made of a softer material to the rest of the stent, or by running an interrupted layer extrusion. Heat bonding or adhesive bonding may be accomplished, for example, using methods commonly employed for plastic tubes and catheters.
Typically, in a ureteral application, the non-extended length of the stent in an embodiment of the invention ranges between about 18 cm to about 30 cm. However, in certain embodiments, the stent has a non-extended length less than 18 cm or greater than 30 cm. In one embodiment, the non-extended length of the stent is about 20 cm. The wall thickness of the stent may vary, or it may be substantially uniform. For example, in an embodiment, the wall thickness of the stent at the flattened part of the distal portion is less than the wall thickness elsewhere along the stent in order to provide increased flexibility of the flattened part of the stent, resulting in reduced irritation in the trigonal region and/or ureteral vesical junction. The wall thickness at a given part of the stent is typically between about 0.05 mm and about 0.35 mm, but the wall thickness may be outside this range in some embodiments. In one embodiment, the wall thickness is 0.2 mm. The average outside diameter of the stent is typically between about 1.6 mm and about 3.3 mm, but may be outside this range. In one embodiment, the average outside diameter of the stent is about 2 mm. In one embodiment, the outside diameter of the stent is a value ranging from about French size 6 to about French size 12.
While the invention has been particularly shown and described with reference to specific preferred embodiments, it should be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Liu, Clifford M., Li, Jianmin E.
Patent | Priority | Assignee | Title |
10080641, | Nov 12 2013 | GYRUS ACMI, INC | Ureteral stents with waveform interlayers and interstitching |
10201441, | Oct 30 2002 | Boston Scientific Scimed, Inc. | Linearly expandable ureteral stent |
10307564, | Jul 20 2015 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
10384043, | Sep 26 2008 | ARCHIMEDES VASCULAR, LLC | Devices and methods for control of blood pressure |
10426919, | Jul 20 2015 | Roivios Limited | Systems and methods for inducing negative pressure in a portion of a urinary tract of a patient |
10493232, | Jul 20 2015 | Roivios Limited | Ureteral catheters, bladder catheters, systems, kits and methods for inducing negative pressure to increase renal function |
10499855, | Dec 21 2012 | Canary Medical Switzerland AG | Stent graft monitoring assembly and method of use thereof |
10512713, | Jul 20 2015 | Roivios Limited | Method of removing excess fluid from a patient with hemodilution |
10524694, | Jun 25 2014 | Canary Medical Switzerland AG | Devices, systems and methods for using and monitoring tubes in body passageways |
10610664, | Jul 20 2015 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
10667906, | Nov 25 2008 | Edwards Lifesciences Corporation | Methods of conformal expansion of prosthetic heart valves |
10695161, | Sep 15 2008 | Merit Medical Systems, Inc | Convertible nephroureteral catheter |
10722391, | Aug 12 2014 | Merit Medical Systems, Inc | Systems and methods for coupling and decoupling a catheter |
10765834, | Jul 20 2015 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
10779965, | Nov 06 2013 | Enopace Biomedical Ltd | Posts with compliant junctions |
10799668, | Jul 20 2015 | Roivios Limited | Ureteral catheters, bladder catheters, systems, kits and methods for inducing negative pressure to increase renal function |
10828181, | Sep 09 2011 | Enopace Biomedical Ltd. | Annular antenna |
10918825, | Jul 20 2015 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
10918827, | Jul 20 2015 | Roivios Limited | Catheter device and method for inducing negative pressure in a patient's bladder |
10926062, | Jul 20 2015 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
10933227, | Dec 01 2017 | Gyrus ACMI, Inc.; GYRUS ACMI, INC , D B A OLYMPUS SURGICAL TECHNOLOGIES AMERICA | Ureteral stent |
10980969, | Jul 20 2015 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
10980970, | Jul 20 2015 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
10980989, | Jul 20 2015 | Strataca Systems Limited | Systems, kits and methods for inducing negative pressure to increase renal function |
11039914, | Oct 22 2018 | SEVRO TECHNOLOGIES LLC | Variable length stent |
11040172, | Jul 20 2015 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
11040180, | Jul 20 2015 | Roivios Limited | Systems, kits and methods for inducing negative pressure to increase renal function |
11045623, | Jul 20 2015 | Strataca Systems Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
11077284, | Jul 20 2015 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
11096774, | Dec 09 2016 | ZENFLOW, INC. | Systems, devices, and methods for the accurate deployment of an implant in the prostatic urethra |
11197992, | Jul 25 2005 | Enopace Biomedical Ltd | Electrical stimulation of blood vessels |
11213414, | Nov 04 2016 | Boston Scientific Scimed, Inc. | Controlled extension stent |
11229771, | Jul 20 2015 | Roivios Limited | Percutaneous ureteral catheter |
11389079, | Jun 25 2014 | Canary Medical Switzerland AG | Devices, systems and methods for using and monitoring tubes in body passageways |
11389287, | May 19 2017 | Mayo Foundation for Medical Education and Research | Methods and materials for treating urinary calculi |
11400299, | Sep 14 2021 | Rainbow Medical Ltd | Flexible antenna for stimulator |
11420014, | Jul 20 2015 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
11432949, | Nov 06 2013 | Enopace Biomedical Ltd. | Antenna posts |
11433217, | Jul 20 2015 | Roivios Limited | Systems and methods for inducing negative pressure in a portion of a urinary tract of a patient |
11433219, | Jul 20 2015 | Roivios Limited | Coated urinary catheter or ureteral stent and method |
11439493, | Sep 15 2008 | Merit Medical Systems, Inc | Convertible nephroureteral catheter |
11445978, | Dec 21 2012 | Canary Medical Switzerland AG | Stent graft monitoring assembly and method of use thereof |
11471583, | Jul 20 2015 | Roivios Limited | Method of removing excess fluid from a patient with hemodilution |
11478607, | Jul 20 2015 | Roivios Limited | Systems and methods for inducing negative pressure in a portion of a urinary tract of a patient |
11511075, | Jul 20 2015 | Roivios Limited | Coated urinary catheter or ureteral stent and method |
11541205, | Jul 20 2015 | Roivios Limited | Coated urinary catheter or ureteral stent and method |
11612714, | Jul 20 2015 | Roivios Limited | Systems and methods for inducing negative pressure in a portion of a urinary tract of a patient |
11696999, | Jul 20 2015 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
11752300, | Jul 20 2015 | Strataca Systems Limited | Catheter device and method for inducing negative pressure in a patient's bladder |
11779737, | Dec 01 2017 | Gyrus ACMI, Inc. | Ureteral stent |
11819637, | Jul 20 2015 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
11826516, | Jun 24 2020 | Ureteral bypass devices and procedures | |
11890213, | Nov 19 2019 | ZENFLOW, INC. | Systems, devices, and methods for the accurate deployment and imaging of an implant in the prostatic urethra |
11896785, | Jul 20 2015 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
11903859, | Dec 09 2016 | ZENFLOW, INC. | Methods for deployment of an implant |
11904113, | Jul 20 2015 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
11904121, | Jul 20 2015 | Roivios Limited | Negative pressure therapy system |
11911141, | Jun 25 2014 | Canary Medical Switzerland AG | Devices, systems and methods for using and monitoring tubes in body passageways |
11918754, | Jul 20 2015 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
11931275, | Aug 12 2014 | Merit Medical Systems, Inc. | Systems and methods for coupling and decoupling a catheter |
11998348, | Jun 25 2014 | Canary Medical Switzerland AG | Devices, systems and methods for using and monitoring heart valves |
11998438, | Dec 09 2016 | ZENFLOW, INC. | Systems, devices, and methods for the accurate deployment of an implant in the prostatic urethra |
12059543, | Aug 25 2017 | Roivios Limited | Indwelling pump for facilitating removal of urine from the urinary tract |
12064567, | Jul 20 2015 | Roivios Limited | Percutaneous urinary catheter |
12076225, | Jul 20 2015 | Roivios Limited | Ureteral catheters, bladder catheters, systems, kits and methods for inducing negative pressure to increase renal function |
12083029, | Nov 04 2016 | Boston Scientific Scimed, Inc. | Controlled extension stent |
12090040, | Dec 09 2016 | ZENFLOW, INC. | Methods for deployment of an implant |
7550012, | Aug 31 2005 | Cook Medical Technologies LLC | Stent for implantation |
7789915, | Aug 31 2005 | Cook Medical Technologies LLC | Stent for implantation |
8007702, | Oct 30 2002 | Boston Scientific Scimed, Inc. | Methods of manufacturing linearly expandable ureteral stents |
8241548, | Oct 30 2002 | Boston Scientific Scimed, Inc. | Methods of manufacturing linearly expandable ureteral stents |
8538535, | Aug 05 2010 | Enopace Biomedical Ltd | Enhancing perfusion by contraction |
8568643, | Oct 30 2002 | Boston Scientific Scimed, Inc. | Methods of manufacturing linearly expandable ureteral stents |
8591567, | Nov 25 2008 | Edwards Lifesciences Corporation | Apparatus and method for in situ expansion of prosthetic device |
8626290, | Jan 31 2008 | ENOPACE BIOMEDICAL | Acute myocardial infarction treatment by electrical stimulation of the thoracic aorta |
8626299, | Jan 31 2008 | Enopace Biomedical Ltd | Thoracic aorta and vagus nerve stimulation |
8649863, | Dec 20 2010 | Rainbow Medical Ltd | Pacemaker with no production |
8764847, | Sep 16 2008 | C. R. Bard, Inc. | Stent |
8808261, | Dec 15 2010 | Ureteral bypass devices and procedures | |
8855783, | Sep 09 2011 | Enopace Biomedical Ltd | Detector-based arterial stimulation |
8862243, | Jul 25 2005 | Enopace Biomedical Ltd | Electrical stimulation of blood vessels |
8920513, | Aug 27 2010 | Anti-refluxive and trigone sparing internal ureteral stent | |
8923972, | Jul 25 2005 | ARCHIMEDES VASCULAR, LLC | Elliptical element for blood pressure reduction |
9060888, | Oct 30 2002 | Boston Scientific Scimed, Inc. | Method of disposing a linearly expandable ureteral stent within a patient |
9125567, | Sep 26 2008 | ARCHIMEDES VASCULAR, LLC | Devices and methods for control of blood pressure |
9125732, | Sep 26 2008 | ARCHIMEDES VASCULAR, LLC | Devices and methods for control of blood pressure |
9242079, | Nov 12 2013 | Gyrus ACMI, Inc. | Ureteral stents with waveform interlayers and interstitching |
9254203, | Aug 20 2012 | Boston Scientific Scimed, Inc. | Delivery device |
9314334, | Nov 25 2008 | Edwards Lifesciences Corporation | Conformal expansion of prosthetic devices to anatomical shapes |
9386991, | Feb 02 2012 | Rainbow Medical Ltd | Pressure-enhanced blood flow treatment |
9457174, | Jul 25 2005 | ARCHIMEDES VASCULAR, LLC | Elliptical element for blood pressure reduction |
9498356, | Dec 19 2012 | Cook Medical Technologies, LLC | Flexible stent and delivery system |
9510934, | Jul 20 2012 | Cook Medical Technologies LLC | Implantable medical device having a sleeve |
9526637, | Sep 09 2011 | Enopace Biomedical Ltd | Wireless endovascular stent-based electrodes |
9550048, | Jul 25 2005 | ARCHIMEDES VASCULAR, LLC | Elliptical element for blood pressure reduction |
9592136, | Jul 25 2005 | ARCHIMEDES VASCULAR, LLC | Devices and methods for control of blood pressure |
9642726, | May 05 2010 | ARCHIMEDES VASCULAR, LLC | Devices and methods for control of blood pressure |
9649487, | Aug 05 2010 | Enopace Biomedical Ltd | Enhancing perfusion by contraction |
9744331, | Jul 20 2015 | Roivios Limited | Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion |
9763814, | Oct 24 2014 | Cook Medical Technologies LLC | Elongate medical device |
9956100, | Aug 12 2014 | Merit Medical Systems, Inc | Systems and methods for coupling and decoupling a catheter |
ER211, | |||
ER4755, |
Patent | Priority | Assignee | Title |
4531933, | Dec 07 1982 | C. R. Bard, Inc. | Helical ureteral stent |
4610657, | Jan 03 1984 | Cabot Technology Corporation | Ureteral stent |
4643716, | Sep 26 1984 | The Kendall Company | Multi-size ureteral stent |
4671795, | Nov 19 1984 | Permanent/retrievable ureteral catheter | |
4713049, | Aug 05 1986 | Cabot Technology Corporation | Ureteral stent kit |
4790810, | Nov 04 1985 | AMS Research Corporation | Ureteral connector stent |
4813925, | Apr 21 1987 | Cabot Technology Corporation | Spiral ureteral stent |
4820298, | Nov 20 1987 | DEVICE DEVELOPMENTS, INC | Internal vascular prosthesis |
4874360, | Jul 01 1988 | Cabot Technology Corporation | Ureteral stent system |
5019102, | Dec 10 1987 | Anti-refluxive internal ureteral stent with a dynamic hood-valve at the vesical end for prevention of urinary reflux into the upper urinary tract upon increase of vesical pressure | |
5116309, | Jan 25 1989 | Cabot Technology Corporation | Ureteral stent-catheter system having varying diameter stent |
5141502, | Aug 28 1991 | Ureteral stent | |
5221253, | Jan 25 1989 | Cabot Technology Corporation | Urological stent-catheter system having varing diameter stent |
5246446, | Jun 25 1990 | Uterine incision compression device | |
5401257, | Apr 27 1993 | Boston Scientific Scimed, Inc | Ureteral stents, drainage tubes and the like |
5514176, | Jan 20 1995 | Cook Medical Technologies LLC | Pull apart coil stent |
5647843, | May 24 1996 | Cook Medical Technologies LLC | Anti-reflux ureteral stent |
5681274, | Mar 31 1995 | Boston Scientific Scimed, Inc | Variable length uretheral stent |
5769812, | Jul 16 1991 | Edwards Lifesciences, LLC | System for cardiac procedures |
5795319, | Mar 07 1997 | GYRUS ACMI, INC | Easily removable ureteral stent |
5911710, | May 03 1997 | BOSTON SCIENTIFIC GLENS FALLS CORP | Medical insertion device with hemostatic valve |
5919183, | Apr 25 1996 | Smiths Group PLC | Introducers and assemblies |
5938653, | Jun 09 1997 | Boston Scientific Scimed, Inc | Catheter having controlled flexibility and method of manufacture |
6332892, | Mar 02 1999 | Boston Scientific Scimed, Inc | Medical device with one or more helical coils |
6620202, | Oct 16 2001 | SciMed Life Systems, INC | Medical stent with variable coil and related methods |
20020173754, | |||
20030171708, | |||
20030199986, | |||
20040087886, | |||
WO191668, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Dec 18 2002 | CLIFFORD M LIU | SciMed Life Systems, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 013945 | /0346 | |
Dec 18 2002 | LI, JIANMIN | SciMed Life Systems, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 013945 | /0346 | |
Jan 22 2003 | Boston Scientific Scimed, Inc. | (assignment on the face of the patent) | / | |||
Dec 22 2004 | SciMed Life Systems, INC | Boston Scientific Scimed, Inc | CHANGE OF NAME SEE DOCUMENT FOR DETAILS | 016668 | /0847 |
Date | Maintenance Fee Events |
Mar 28 2006 | ASPN: Payor Number Assigned. |
Sep 28 2009 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Oct 16 2013 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Nov 07 2017 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
May 16 2009 | 4 years fee payment window open |
Nov 16 2009 | 6 months grace period start (w surcharge) |
May 16 2010 | patent expiry (for year 4) |
May 16 2012 | 2 years to revive unintentionally abandoned end. (for year 4) |
May 16 2013 | 8 years fee payment window open |
Nov 16 2013 | 6 months grace period start (w surcharge) |
May 16 2014 | patent expiry (for year 8) |
May 16 2016 | 2 years to revive unintentionally abandoned end. (for year 8) |
May 16 2017 | 12 years fee payment window open |
Nov 16 2017 | 6 months grace period start (w surcharge) |
May 16 2018 | patent expiry (for year 12) |
May 16 2020 | 2 years to revive unintentionally abandoned end. (for year 12) |